Search Orphan Drug Designations and Approvals
-
Generic Name: | Recombinant Bispecific antibody targeting CD123 and CD3 |
---|---|
Date Designated: | 11/26/2019 |
Orphan Designation: | Treatment of acute myelogenous leukemia |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Aptevo Research and Development 2401 Fourth Avenue Suite 1050 Seattle, Washington 98121 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-